Management of Thrombosis Risk with Ponatinib and other TKIs for CML?

How Should Chronic-phase CML Management be Influenced by RT-PCR Results at 3 Months+Подробнее

CML molecular monitoring: Practical adviceПодробнее

Outcomes of patients with CML-CP treated with ponatinib vs 2G-TKIs in the third-line settingПодробнее

Case 2: Ponatinib for T315I-Mutated CMLПодробнее

FDA Approves New Dosing for Ponatinib to Treat Chronic Myeloid LeukemiaПодробнее

Modelling ponatinib resistance in BCR-ABL1 cell linesПодробнее

Case 1: Ponatinib in Chronic-Phase CMLПодробнее

Safety of ponatinib in chronic-phase chronic myeloid leukemia (CML) patientsПодробнее

Dr. Cortes Discusses Approval of Ponatinib for Adults with Chronic-phase CMLПодробнее

Bosutinib Versus Ponatinib in R/R CMLПодробнее

iCMLf Conversations: Management of Advanced Phases of CMLПодробнее

Is Ponatinib Safe for Treating CML?Подробнее

Ponatinib in chronic-phase CML patients with prior second generation TKI exposureПодробнее

Spotlight on APL, CML, and multiple myelomaПодробнее

Debate: Chronic-Phase CML Patient Develops a T315I Mutation - Experimental TherapyПодробнее

Early Intervention With Ponatinib in Treatment of CMLПодробнее

Interim Data Analysis Suggests Ponatinib to be Favorable TKI Treatment Among CML PatientsПодробнее

Resistance to Targeted-TKI Treatment in Patients With CMLПодробнее